Protocol for a two-arm pragmatic stepped-wedge hybrid effectiveness-implementation trial evaluating Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship (ENCOMPASS).


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
02 Jun 2021
Historique:
received: 03 05 2021
accepted: 12 05 2021
entrez: 3 6 2021
pubmed: 4 6 2021
medline: 5 6 2021
Statut: epublish

Résumé

Sepsis survivors experience high morbidity and mortality, and healthcare systems lack effective strategies to address patient needs after hospital discharge. The Sepsis Transition and Recovery (STAR) program is a navigator-led, telehealth-based multicomponent strategy to provide proactive care coordination and monitoring of high-risk patients using evidence-driven, post-sepsis care tasks. The purpose of this study is to evaluate the effectiveness of STAR to improve outcomes for sepsis patients and to examine contextual factors that influence STAR implementation. This study uses a hybrid type I effectiveness-implementation design to concurrently test clinical effectiveness and gather implementation data. The effectiveness evaluation is a two-arm, pragmatic, stepped-wedge cluster randomized controlled trial at eight hospitals in North Carolina comparing clinical outcomes between sepsis survivors who receive Usual Care versus care delivered through STAR. Each hospital begins in a Usual Care control phase and transitions to STAR in a randomly assigned sequence (one every 4 months). During months that a hospital is allocated to Usual Care, all eligible patients will receive usual care. Once a hospital transitions to STAR, all eligible patients will receive STAR during their hospitalization and extending through 90 days from discharge. STAR includes centrally located nurse navigators using telephonic counseling and electronic health record-based support to facilitate best-practice post-sepsis care strategies including post-discharge review of medications, evaluation for new impairments or symptoms, monitoring existing comorbidities, and palliative care referral when appropriate. Adults admitted with suspected sepsis, defined by clinical criteria for infection and organ failure, are included. Planned enrollment is 4032 patients during a 36-month period. The primary effectiveness outcome is the composite of all-cause hospital readmission or mortality within 90 days of discharge. A mixed-methods implementation evaluation will be conducted before, during, and after STAR implementation. This pragmatic evaluation will test the effectiveness of STAR to reduce combined hospital readmissions and mortality, while identifying key implementation factors. Results will provide practical information to advance understanding of how to integrate post-sepsis management across care settings and facilitate implementation, dissemination, and sustained utilization of best-practice post-sepsis management strategies in other heterogeneous healthcare delivery systems. NCT04495946 . Submitted July 7, 2020; Posted August 3, 2020.

Sections du résumé

BACKGROUND BACKGROUND
Sepsis survivors experience high morbidity and mortality, and healthcare systems lack effective strategies to address patient needs after hospital discharge. The Sepsis Transition and Recovery (STAR) program is a navigator-led, telehealth-based multicomponent strategy to provide proactive care coordination and monitoring of high-risk patients using evidence-driven, post-sepsis care tasks. The purpose of this study is to evaluate the effectiveness of STAR to improve outcomes for sepsis patients and to examine contextual factors that influence STAR implementation.
METHODS METHODS
This study uses a hybrid type I effectiveness-implementation design to concurrently test clinical effectiveness and gather implementation data. The effectiveness evaluation is a two-arm, pragmatic, stepped-wedge cluster randomized controlled trial at eight hospitals in North Carolina comparing clinical outcomes between sepsis survivors who receive Usual Care versus care delivered through STAR. Each hospital begins in a Usual Care control phase and transitions to STAR in a randomly assigned sequence (one every 4 months). During months that a hospital is allocated to Usual Care, all eligible patients will receive usual care. Once a hospital transitions to STAR, all eligible patients will receive STAR during their hospitalization and extending through 90 days from discharge. STAR includes centrally located nurse navigators using telephonic counseling and electronic health record-based support to facilitate best-practice post-sepsis care strategies including post-discharge review of medications, evaluation for new impairments or symptoms, monitoring existing comorbidities, and palliative care referral when appropriate. Adults admitted with suspected sepsis, defined by clinical criteria for infection and organ failure, are included. Planned enrollment is 4032 patients during a 36-month period. The primary effectiveness outcome is the composite of all-cause hospital readmission or mortality within 90 days of discharge. A mixed-methods implementation evaluation will be conducted before, during, and after STAR implementation.
DISCUSSION CONCLUSIONS
This pragmatic evaluation will test the effectiveness of STAR to reduce combined hospital readmissions and mortality, while identifying key implementation factors. Results will provide practical information to advance understanding of how to integrate post-sepsis management across care settings and facilitate implementation, dissemination, and sustained utilization of best-practice post-sepsis management strategies in other heterogeneous healthcare delivery systems.
TRIAL REGISTRATION BACKGROUND
NCT04495946 . Submitted July 7, 2020; Posted August 3, 2020.

Identifiants

pubmed: 34078374
doi: 10.1186/s12913-021-06521-1
pii: 10.1186/s12913-021-06521-1
pmc: PMC8170654
doi:

Banques de données

ClinicalTrials.gov
['NCT04495946']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

544

Subventions

Organisme : NINR NIH HHS
ID : R01 NR018434
Pays : United States
Organisme : NLM NIH HHS
ID : R21 LM013373
Pays : United States
Organisme : NINR NIH HHS
ID : R01NR018434
Pays : United States

Références

Crit Care Clin. 2018 Jan;34(1):175-188
pubmed: 29149939
JAMA. 2018 Jan 2;319(1):62-75
pubmed: 29297082
Am J Prev Med. 2016 Oct;51(4):454-62
pubmed: 27242081
Health Syst Reform. 2016 Jan 2;2(1):32-38
pubmed: 31514650
Prev Chronic Dis. 2011 Nov;8(6):A143
pubmed: 22005636
JAMA Cardiol. 2018 Jan 1;3(1):44-53
pubmed: 29128869
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Gen Intern Med. 2020 Apr;35(4):1060-1068
pubmed: 31993948
JAMA. 2010 Oct 27;304(16):1787-94
pubmed: 20978258
PLoS Med. 2012;9(11):e1001346
pubmed: 23185138
Value Health. 2015 Mar;18(2):161-72
pubmed: 25773551
Trials. 2019 Nov 29;20(1):660
pubmed: 31783900
Lancet Respir Med. 2015 Jan;3(1):61-9
pubmed: 25434614
Adv Health Care Manag. 2011;11:149-83
pubmed: 22908669
Epidemiology. 2009 Nov;20(6):863-71
pubmed: 19806059
Ann Intern Med. 2013 Mar 5;158(5 Pt 1):ITC3-1
pubmed: 23460071
JAMA Netw Open. 2019 Feb 1;2(2):e187571
pubmed: 30768188
JAMA. 2017 Jan 17;317(3):290-300
pubmed: 28114553
Implement Sci. 2016 May 17;11:72
pubmed: 27189233
Health Aff (Millwood). 2009 Jan-Feb;28(1):75-85
pubmed: 19124857
BMJ. 2002 Sep 21;325(7365):652-4
pubmed: 12242181
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Trials. 2015 Aug 17;16:354
pubmed: 26282553
JAMA. 2014 Apr 2;311(13):1308-16
pubmed: 24638143
Am J Respir Crit Care Med. 2013 Sep 1;188(5):586-92
pubmed: 23848267
JAMA. 2020 Aug 25;324(8):739-740
pubmed: 32777028
Crit Care Med. 2009 Apr;37(4):1268-74
pubmed: 19242321
Crit Care. 2017 Feb 24;21(1):38
pubmed: 28231816
Intensive Care Med. 2020 Apr;46(4):619-636
pubmed: 31974919
Crit Care Med. 2004 Apr;32(4):981-5
pubmed: 15071389
Mol Med. 2019 Dec 31;26(1):6
pubmed: 31892321
Intensive Care Med. 2015 Aug;41(8):1433-44
pubmed: 26109398
Stat Med. 2016 Nov 20;35(26):4718-4728
pubmed: 27350420
Contemp Clin Trials. 2007 Feb;28(2):182-91
pubmed: 16829207
J Cardiopulm Rehabil Prev. 2013 Sep-Oct;33(5):281-91
pubmed: 23823904
Semin Oncol Nurs. 2013 May;29(2):72-5
pubmed: 23651676
West J Emerg Med. 2008 Jan;9(1):6-8
pubmed: 19561695
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Crit Care Med. 2019 Sep;47(9):1194-1200
pubmed: 31241499
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
JAMA. 2017 Oct 3;318(13):1241-1249
pubmed: 28903154
Intensive Care Med. 2020 May;46(5):930-942
pubmed: 32072303
N Engl J Med. 2016 Apr 21;374(16):1543-51
pubmed: 26910198
Ann Intensive Care. 2017 Dec;7(1):28
pubmed: 28271450
N Engl J Med. 2008 Mar 6;358(10):1064-71
pubmed: 18322289
Am J Respir Crit Care Med. 2019 Oct 15;200(8):972-981
pubmed: 31161771
Crit Care Med. 2013 Aug;41(8):1832-43
pubmed: 23782967
J Clin Nurs. 2018 Aug;27(15-16):3104-3114
pubmed: 29729037
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
BMC Med Res Methodol. 2016 Jun 06;16:69
pubmed: 27267471
Eff Clin Pract. 1998 Aug-Sep;1(1):2-4
pubmed: 10345255
Crit Care Med. 2014 Oct;42(10):2211-8
pubmed: 25054672
N Engl J Med. 2012 Apr 12;366(15):1364-6
pubmed: 22455754
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Int J Epidemiol. 2012 Apr;41(2):514-20
pubmed: 22253321
Am J Respir Crit Care Med. 2012 Aug 15;186(4):302-4
pubmed: 22896591
Pediatrics. 2016 Sep;138(3):
pubmed: 27507894
Crit Care Med. 2007 Jan;35(1):192-8
pubmed: 17110874
South Med J. 2009 Nov;102(11):1150-7
pubmed: 19864995
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Ann Intern Med. 2018 Feb 20;168(4):266-275
pubmed: 29404582
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Clin Epidemiol. 2017 Jun 08;9:331-338
pubmed: 28652815
Health Aff (Millwood). 2011 Apr;30(4):746-54
pubmed: 21471497
Int J Technol Assess Health Care. 2020 Apr;36(2):145-151
pubmed: 32114996
Ann Intern Med. 2004 Oct 5;141(7):533-6
pubmed: 15466770
Am J Prev Med. 2012 Sep;43(3):309-19
pubmed: 22898125
JAMA. 2017 Feb 7;317(5):530-531
pubmed: 28114505
J Gen Intern Med. 2019 Jan;34(1):58-64
pubmed: 30109585
JAMA. 2014 Jul 2;312(1):90-2
pubmed: 24838355
Health Serv Res. 2007 Aug;42(4):1758-72
pubmed: 17286625
BMJ. 2016 May 17;353:i2375
pubmed: 27189000
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Chest. 2017 Mar;151(3):586-596
pubmed: 27876592
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72
pubmed: 26414292
Crit Care Med. 2018 Jun;46(6):843-849
pubmed: 29432349
Nurse Res. 2013 Mar;20(4):36-43
pubmed: 23520711
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
Ann Am Thorac Soc. 2020 Jan;17(1):89-97
pubmed: 31644304
Ann Intern Med. 2011 Oct 18;155(8):520-8
pubmed: 22007045
Curr Opin Crit Care. 2018 Oct;24(5):401-409
pubmed: 30063492
JAMA. 2015 Mar 10;313(10):1055-7
pubmed: 25756444
N Engl J Med. 2016 Oct 27;375(17):1610-1612
pubmed: 27783911
BMJ. 2015 May 08;350:h2147
pubmed: 25956159
BMJ. 2018 Nov 9;363:k1614
pubmed: 30413417

Auteurs

Marc Kowalkowski (M)

Center for Outcomes Research and Evaluation, Atrium Health, 1300 Scott Ave, Charlotte, NC, 28203, USA. Marc.Kowalkowski@AtriumHealth.org.

Tara Eaton (T)

Center for Outcomes Research and Evaluation, Atrium Health, 1300 Scott Ave, Charlotte, NC, 28203, USA.

Andrew McWilliams (A)

Center for Outcomes Research and Evaluation, Atrium Health, 1300 Scott Ave, Charlotte, NC, 28203, USA.
Department of Internal Medicine, Atrium Health, Charlotte, USA.

Hazel Tapp (H)

Department of Family Medicine, Atrium Health, Charlotte, USA.

Aleta Rios (A)

Ambulatory Care Management, Atrium Health, Charlotte, USA.

Stephanie Murphy (S)

Department of Internal Medicine, Atrium Health, Charlotte, USA.

Ryan Burns (R)

Center for Outcomes Research and Evaluation, Atrium Health, 1300 Scott Ave, Charlotte, NC, 28203, USA.

Bella Gutnik (B)

Center for Outcomes Research and Evaluation, Atrium Health, 1300 Scott Ave, Charlotte, NC, 28203, USA.

Katherine O'Hare (K)

Department of Family Medicine, Atrium Health, Charlotte, USA.

Lewis McCurdy (L)

Division of Infectious Disease, Department of Internal Medicine, Atrium Health, Charlotte, USA.

Michael Dulin (M)

Academy for Population Health Innovation, University of North Carolina Charlotte & Mecklenburg County Public Health Department, Charlotte, USA.
Department of Public Health Sciences, University of North Carolina Charlotte, Charlotte, USA.

Christopher Blanchette (C)

Department of Public Health Sciences, University of North Carolina Charlotte, Charlotte, USA.
Health Economics and Outcomes Research Strategy, Novo Nordisk, Plainsboro Township, USA.

Shih-Hsiung Chou (SH)

Center for Outcomes Research and Evaluation, Atrium Health, 1300 Scott Ave, Charlotte, NC, 28203, USA.

Scott Halpern (S)

Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

Derek C Angus (DC)

Clinical Research, Investigation, and Systems Modeling of Acute illness (CRISMA) Center, University of Pittsburgh, Pittsburgh, USA.
Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, USA.

Stephanie P Taylor (SP)

Department of Internal Medicine, Atrium Health, Charlotte, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH